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RESEARCH ARTICLE Open Access
Chemokine receptor co-expression reveals
aberrantly distributed TH effector memory
cells in GPA patients
Lucas L. Lintermans1, Abraham Rutgers1, Coen A. Stegeman2, Peter Heeringa3 and Wayel H. Abdulahad1,3*
Abstract
Background: Persistent expansion of circulating CD4+ effector memory T cells (TEM) in patients with granulomatosis
with polyangiitis (GPA) suggests their fundamental role in disease pathogenesis. Recent studies have shown that
distinct functional CD4+ TEM cell subsets can be identified based on expression patterns of chemokine receptors.
The current study aimed to determine different CD4+ TEM cell subsets based on chemokine receptor expression in
peripheral blood of GPA patients. Identification of particular circulating CD4+ TEM cells subsets may reveal distinct
contributions of specific CD4+ TEM subsets to the disease pathogenesis in GPA.
Method: Peripheral blood of 63 GPA patients in remission and 42 age- and sex-matched healthy controls was stained
immediately after blood withdrawal with fluorochrome-conjugated antibodies for cell surface markers (CD3, CD4,
CD45RO) and chemokine receptors (CCR4, CCR6, CCR7, CRTh2, CXCR3) followed by flow cytometry analysis. CD4+ TEM
memory cells (CD3+CD4+CD45RO+CCR7-) were gated, and the expression patterns of chemokine receptors CXCR3+CCR4-
CCR6-CRTh2-, CXCR3-CCR4+CCR6-CRTh2+, CXCR3-CCR4+CCR6+CRTh2-, and CXCR3+CCR4-CCR6+CRTh2- were used to
distinguish TEM1, TEM2, TEM17, and TEM17.1 cells, respectively.
Results: The percentage of CD4+ TEM cells was significantly increased in GPA patients in remission compared to HCs.
Chemokine receptor co-expression analysis within the CD4+ TEM cell population demonstrated a significant increase in
the proportion of TEM17 cells with a concomitant significant decrease in the TEM1 cells in GPA patients compared to HC.
The percentage of TEM17 cells correlated negatively with TEM1 cells in GPA patients. Moreover, the circulating proportion
of TEM17 cells showed a positive correlation with the number of organs involved and an association with the tendency to
relapse in GPA patients. Interestingly, the aberrant distribution of TEM1 and TEM17 cells is modulated in CMV- seropositive
GPA patients.
Conclusions: Our data demonstrates the identification of different CD4+ TEM cell subsets in peripheral blood of GPA
patients based on chemokine receptor co-expression analysis. The aberrant balance between TEM1 and TEM17 cells in
remission GPA patients, showed to be associated with disease pathogenesis in relation to organ involvement, and
tendency to relapse.
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Background
Granulomatosis with polyangiitis (GPA) is a severe sys-
temic autoimmune disease of unknown etiology. The
hallmark of the disease is the presence of antineutrophil
cytoplasmic autoantibodies (ANCAs) mainly directed
against protienase-3 (PR3) [1]. GPA is characterized by
necrotizing granulomatosis in the respiratory tract, and
a systemic vasculitis preferentially affecting pulmonary
and renal small- and medium-sized blood vessels. The
abundance of T cells in these vasculitic and granuloma-
tous lesions of GPA patients support their involvement
in disease pathogenesis [2]. There is substantial evidence
of activated T cells and antigen-driven T cell responses
in GPA [3–5] In addition, remission has been induced
with therapeutics directed against T cells in patients with
refractory GPA [6, 7]. These studies strongly indicate a T
cell-mediated pathology in this disease.
The involvement of cluster of differentiation (CD)4+ T
helper (TH) cells in the pathogenesis of GPA has been
suggested to depend on disease activity, and whether the
disease is localized, i.e. restricted to the respiratory tract,
or generalized. Prior to the discovery of TH17 cells, re-
search in GPA focused on the disturbed balance between
TH1 and TH2 cells. It was found that GPA patients with
active disease demonstrated a dysregulated cytokine pro-
life of circulating T cells with increased IFN-γ produc-
tion versus a normal interleukin (IL)-4 production [8].
Additional studies demonstrated the presence of TH1-as-
sociated markers in the circulation as well as in nasal
granulomatous lesions of patients with localized disease,
while TH2-associated markers were dominant in general-
ized disease [9–11]. More recently, levels of IL-17A, the
TH17-associated cytokine, were found to be elevated in
serum of GPA patients irrespective of active or quiescent
disease [12]. In addition, a relative increase in
autoantigen-specific TH17 cells in GPA patients has been
reported [12, 13].
Defects in regulatory T cell (TREG) function in GPA
patients may contribute to abnormal skewing in TH cell
responses and may result in an expansion of the CD4+
effector memory T (CD4+ TEM) cell population [14]. In
addition, altered TH cell distribution in GPA patients
may be in part driven by chronic cytomegalovirus
(CMV) infection [15]. We have demonstrated previously
that circulating CD4+ TEM cells (CCR7
-CD45RO+) in
GPA patients were proportionally increased during
remission [16], but were decreased during renal active
disease upon migration to the inflammatory site [17].
However, during active renal disease not all circulating
CD4+ TEM cells tend to migrate to the target tissues
[17]. It is possible that a subset of circulating CD4+ TEM
cells have a distinct migratory capacity and pathogenic
function in GPA patients related to distinct clinical
manifestations.
The recruitment of the CD4+ TEM cells to inflamma-
tory sites is orchestrated by their chemokine receptors.
Analysis of chemokine receptor expression has been
instrumental in the characterization of memory TH sub-
sets with distinct cytokine patterns and antigen responses
[18]. The expression pattern of four chemokine receptors
allows the identification of CD4+ TEM subsets, which are
defined as TEM1 [C-C chemokine receptor (CCR)6
- CXC
chemokine receptor 3 (CXCR3)+CCR4+CRTh2-] TEM2
(CCR6-CXCR3-CCR4+CRTh2+), TEM17 (CCR6
+CXCR3-
CCR4+CRTh2-) [19, 20], and a subset that exhibits
both TH17 and TH1 features, referred to as TEM17.1
(CCR6+CXCR3+CCR4- CRTh2-) [21, 22].
The aim of the present study was to determine the
distribution of circulating CD4+ TEM cell subsets based
on chemokine receptor expression in GPA patients.
Identification of particular circulating CD4+ TEM subsets
may reveal distinct associations of specific CD4+ TEM
subsets with clinical manifestations or with autoanti-
bodies in GPA patients.
Methods
Study population
Peripheral blood was collected from 63 GPA patients in
remission (r-GPA) and 42 age- and sex-matched healthy
controls (HCs) in a cross-sectional study..The r-GPA
patients fulfilled the criteria of the American College
of Rheumatology and the Chapel Hill Consensus
Conference definition for GPA [23, 24]. Only patients
with PR3-ANCA positivity at diagnosis, and complete
remission of their disease at the time of sampling,
were included in the study. The PR3-ANCA titers
were measured by indirect immunofluorescence (IIF)
on ethanol-fixed human granulocytes according to the
standard procedure as described previously [25].
ANCA titers lower than 1:20 were considered nega-
tive. Complete remission was defined as the complete
absence of clinical signs and symptoms of active vas-
culitis, as indicated by a score of zero on the Birming-
ham Vasculitis Activity Score (BVAS) [26]. According
to these criteria, blood samples were taken during a
visit to our outpatient clinic.
Disease extent was defined as localized when GPA was
restricted to the upper and lower respiratory tract and
generalized when systemic disease with vasculitis ex-
tended to more clinical manifestations including involve-
ment of kidneys, joints, eye, and nervous system. None
of the patients and controls experienced an infection at
the time of sampling.
Twenty-nine of 63 r-GPA patients were treated with
maintenance immunosuppressive therapy at time of
blood sampling. Three r-GPA patients received azathio-
prine, 12 r-GPA patients received azathioprine in com-
bination with prednisolone, six r-GPA patients were
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treated with low-dose prednisolone, seven r-GPA pa-
tients received low-dose prednisolone in combination
with mycophenolate mofetil (MMF), and one r-GPA
patient was treated with methotrexate.
Detailed clinical and laboratory characteristics of
the patients are summarized in Table 1. All patients
and healthy volunteers provided informed consent
and the local medical ethics committee approved the
study.
Sample preparation and immunophenotyping by flow
cytometry
EDTA-anticoagulated peripheral blood was obtained
by venipuncture from r-GPA patients and HCs.
Whole blood samples were stained within 4 hours
after blood withdrawal with appropriate concentra-
tions of fluorochrome-conjugated monoclonal anti-
bodies for cell surface antigens. The samples were
immediately processed to obtain the most sensitive
detection for the chemokine receptor expression and
to minimize cell manipulation. The peripheral blood
was stained using the following monoclonal antibodies for
cell surface antigens in combination: Alexa Fluor® 700-
conjugated anti-CD3, eFluor® 450 (eF450)-conjugated
anti-CD4 (both from eBioscience, San Diego, CA,
USA), fluorescein isothiocyanate (FITC)-conjugated
anti-CD45RO, phycoerythrin-cyanin7 (PE-C7)-conjugated
anti-CCR7 (both from BD Biosciences, Franklin Lakes, NJ,
USA), PE-conjugated anti-CRTh2, allophycocyanin-C7
(APC-Cy7)-conjugated anti-CXCR3, peridin chlorophyll
α-protein (PerCP-Cy5.5-conjugated anti-CCR4, and Bril-
liant Violet 605™ (BV605)-conjugated anti-CCR6 (all from
BioLegend, San Diego, CA, USA). The appropriated
isotype-matched control antibodies of irrelevant specificity
were added to a separate tube as negative controls. Sam-
ples were incubated for 15 minutes at room temperature.
Afterward, cells were treated with 2 mL diluted FACS
lysing solution (BD Biosciences) for 10 minutes. Finally,
the samples were washed in PBS containing 1% (w/v) bo-
vine serum albumin (BSA), and immediately analyzed by
eight-color flow cytometric analyses on BD™ LSR II flow
cytometer. Data were collected for 1.0 *106 events for each
sample and plotted using Kaluza v1.2 (Beckman Coulter,
Brea, CA, USA). Lymphocytes were gated for analysis
based on forward and side scatter properties. Positively
and negatively stained populations were calculated by
quadrant dot-plot analysis or histograms, determined by
the appropriate isotype controls. Within the CD4+
TEM cell subset (CD4
+CCR7-CD45RO+) the expression
pattern of chemokine receptors CCR6-CXCR3+CCR4-
CRTh2-, CCR6-CXCR3-CCR4+CRTh2+, CCR6+CXCR3-
CCR4+CRTh2-, and CCR6+CXCR3+CCR4-CRTh2- were
used to distinguish TEM1, TEM2, TEM17, and TEM17.1
cells, respectively.
Detection of S. aureus
From 62 r-GPA patients, S. aureus nasal carriers were
determined as described previously [27]. Briefly, S. aureus
Table 1 Laboratory and clinical characteristics of r-GPA patients
and HC
r-GPA HC
Subjects, n (% male) 63 (% 44) 42 (% 40)
Age, mean (range) 62.3 (26.8–85.2) 57.2 (21.5–86.8)
PR3-ANCAa, n (% positive) 39 (% 62)
PR3-ANCA titer, median (range) 1:40 (0–1:640)
Creatinine umol/L, median (range) 86 (52–224)
CRP mg/L, median (range) 2.7 (0.3–99)
eGFR ml/min*1.73 m2, median (range) 64 (21–109)
CMV seropositive, n (% positive) (N.D.) 33 (% 54) (2) 21 (% 58) (6)
S. aureus, n (% positive) (N.D.) 27 (% 44) (1)
BVAS, mean 0
Disease duration in years, median
(range)
9.6 (1.9–42.7)
No. of total relapses, median (range) 1 (0–7)
Relapserb, n (%) 43 (% 68)
Disease type, n (% generalized) 52 (% 83)
Treatment at time of sampling, n (%)
Azathioprine 3 (% 5)
Azathioprine + prednisolone 12 (% 19)
Prednisolone 6 (% 10)
Mycophenolate mofetil +
prednisolone
7 (% 11)
Methotrexate 1 (% 2)
No immunosupressive treatment 34 (% 54)
Co-trimoxazole, high dose/low
dose/no dose
17/15/31
No. of organs involved, median
(range)
3 (1–7)
Clinical manifestations, n (%)
Renal 35 (% 56)
ENT 45 (% 71)
Joints 36 (% 57)
Pulmonary 40 (% 63)
Nervous system 20 (% 32)
Eyes 24 (% 38)
Cutaneous 13 (% 21)
Other 7 (% 11)
Characteristics at sampling time point
BVAS Birmingham Vasculitis Activity Score, CMV cytomegalovirus, CRP C-
reactive protein, eGFR estimated glomerular filtration rate, ENT ear, nose and
throat, GPA granulomatosis with polyangiitis, HC healthy control, PR3-ANCA
antineutrophil cytoplasmic antibodies targeting proteinase 3, r-GPA GPA
patient in remission, S. aureus Staphylococcus aureus
aANCA-positive titer ≥1:40, ANCA-negative ≤1:20
bRelapser: GPA patient that had ≥1 relapse after diagnosis until time
of sampling
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nasal isolates were sampled by rotating a sterile cotton
swab in each anterior nary. Swabs were inoculated on 5%
sheep-blood and salt mannitol agar for 72 h at 35 °C. S.
aureus was identified by coagulase and DNase positivity.
Patients were considered to be chronic nasal carriers
when ≥50% of their nasal cultures grew S. aureus.
CMV ELISA
CMV-specific IgG was determined in serum samples
using an in-house enzyme-linked immunosorbent
assay (ELISA). In brief, 96-well ELISA plates (Greiner,
Kremsmünster, Austria) were coated overnight with
lysates of CMV-infected fibroblasts. Lysates of non-
infected fibroblasts were used as negative controls.
Following coating, serial (1:100–1:3200) dilutions of
serum samples were incubated for 45 minutes. Next, goat
anti-human IgG-HRP (Southern Biotech, Birmingham, AL,
USA) was added and incubated for 45 minutes. Samples
were incubated with TBE substrate (Sigma-Aldrich, St.
Louis, MO, USA) for 15 minutes and the reaction was
stopped with sulfuric acid. The plates were scanned on a
Versamax reader (Molecular Devices, Sunnyvale, CA, USA).
A pool of sera from three CMV-seropositive individuals with
known concentrations of CMV-specific IgG was used to
quantify levels of CMV-specific IgG in the tested samples.
Statistical analysis
Statistical analysis was performed using SPSS v22 (IBM
Corporation, Armonk, NY, USA) and GraphPad prism v5.0
(GraphPad Software, San Diego, CA, USA). Data are pre-
sented as median values. Data were analyzed with the
D’Agostino-Pearson omnibus normality test for Gaussian
distribution. For comparison between r-GPA patients and
HCs the unpaired t test was used for data with Gaussian
distribution and the Mann-Whitney U test for data without
Gaussian distribution. For intra-individual comparison of
values at multiple time points during follow-up, repeated
measures analysis of variance was used if data were nor-
mally distributed and a Friedman test was used if data had a
non-Gaussian distribution. The association between clinical
parameters and CD4+ TEM cell subsets in inclusion samples
of r-GPA patients was investigated using the Spearman’s
rank correlation coefficient. In order to account for interac-
tions of CMV and age on the percentage of CD4+T cells
subsets and CD4+TEM cell subsets we used a linear (Enter)
regression analysis. Non-normally distributed data were log-
transformed. Differences were considered statistically sig-
nificant at two-sided p values equal to or less than 0.05.
Results
Higher frequency of CD4+ TEM cells in peripheral blood of
GPA patients in remission
We have previously reported that r-GPA patients have
an increased percentage of circulating CD4+ TEM cells
compared to HC [16]. Here, we confirm that within the
CD4+ T cell population in the peripheral blood of r-GPA
patients the frequency of CD4+ TEM cells was signifi-
cantly higher compared to HCs (Fig. 1b). In addition,
the frequency of CD4+ TNaïve cells was significantly
lower in r-GPA patients compared to HCs, whereas the
proportions of CD4+ TCM cells did not differ between
r-GPA patients and HCs. The proportions of CD4+
TTD cells were higher in r-GPA compared to HCs.
Increased frequency of CD4+TEM17 and decreased
frequency of CD4+TEM1 in peripheral blood of patients
with GPA
Having demonstrated a significant increase in the frequency
of CD4+ TEM cells in r-GPA patients we next zoomed in on
the phenotypic distribution within this expanded popula-
tion. As mentioned earlier, CD4+ TEM cell population can
be subdivided into four TEM subsets based on their
differential expression of the chemokine receptors
CCR6, CCR4, CXCR3 and CRTh2. We applied a
chemokine receptor gating strategy, as shown in
Fig. 1a, to identify the distribution of circulating TEM1
(CCR6-CXCR3+CCR4-CRTh2-), TEM2 (CCR6
-CXCR3-
CCR4+CRTh2+), TEM17 (CCR6
+CXCR3-CCR4+CRTh2-),
and TEM17.1 (CCR6
+CXCR3+CCR4-CRTh2-) cell subsets
among the CD4+ TEM cells. The analysis demonstrated a
significant decrease in the frequency of TEM1 and
TEM17.1 cells in r-GPA patients compared to HCs (Fig. 1c).
The frequencies of TEM17 cells were significant higher in
r-GPA compared to HCs. No statistical significant differ-
ence was reached for the distribution of TEM2 cells
between r-GPA patients and HCs. In addition, no changes
were observed in the percentages of both TEM1, and
TEM17 subsets in three consecutive samples during
6 months of follow-up in individual r-GPA patients (data
not shown). Furthermore, we observed CXCR3+CCR4+
(double positive, DP) and CXCR3-CCR4- (double negative,
DN) CCR6+ TEM cells. Although little is known about the
function of these cells, it has been described that the
DP CCR6+ TEM cells produce low levels of IL-17A and
RORC with intermediate IFN-γ and T-bet levels [28].
In our study, we did not observe differences in these
unclassified DP and DN population of either CCR6+ or
CCR6- CD4+TEM cells between r-GPA patients and
HCs (data not shown).
The frequency of TEM17 cells negatively correlates with
the frequency of TEM1 cells in peripheral blood of r-GPA
patients
In vitro and in vivo studies have provided evidence that
TH1 and TH17 cell responses counterregulate each other
during disease development in GPA [13, 29]. Therefore, we
investigated whether the increased proportion of TEM17
cells correlated with the decreased proportion of TEM1
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cells. As shown in Fig. 2, a significant negative correlation
between decreased proportions of TEM1 cells and in-
creased proportions of TEM17 cells was observed in r-GPA
patients (Spearman’s rho = -0.844, p < 0.0001). However,
neither TEM2 cells nor TEM17.1 cells correlated signifi-
cantly with TEM17 cells (Fig. 2a). Similar observations were
found for HCs, although the correlation between TEM1
and TEM17 cells (Spearman’s rho = −0.554) was less
pronounced in comparison to r-GPA patients (Spearman’s
rho = −0.844) (Fig. 2b).
Immunosuppressive therapy and the imbalance in CD4+
TEM cell subsets
To address the question whether current immunosup-
pressive treatment influences the imbalance in TEM1
and TEM17 cell subsets, r-GPA patients were separated
Fig. 1 T cell subset distribution between HC and r-GPA patients. a Gating strategy of CD4+ TEM cell subsets using chemokine receptor expression
patterns. The flow cytometry plots show sequential gating (dashed arrows) to identify different CD4+ TEM cell subsets within the CD4
+TEM cell
population. CD4+ T cell subsets from peripheral blood were identified based on the expression of CCR7 and CD45RO. Within CD4+TEM cells CCR6
-
and CCR6+ cells were identified based on the isotype (grey histogram with dashed line). Within CCR6- CD4+TEM cells expression of CXCR3 and
CCR4 was analyzed to identify TEM1 cells (CD4
+CD45RO+CCR7-CCR6-CXCR3+CCR4-). Expression of CRTh2 was used to identify lineage-committed
TEM2 cells (CD4
+CD45RO+CCR7-CCR6-CXCR3-CCR4+CRTh2+) derived from CCR6-CXCR3-CCR4+ CD4+TEM cells. The CXCR3 and CCR4 expression was
also analyzed on CCR6+ CD4+TEM cells to identify TEM17 cells (CD4
+CD45RO+CCR7-CCR6+CXCR3-CCR4+), and TEM17.1 cells (CD4
+CD45RO+CCR7-
CCR6+CXCR3+CCR4-). The unclassified populations within the CCR6- and CCR6+ populations were identified, that were double-negative (DN) or
double-positive (DP) for CXCR3 and CCR4. Representative flow cytometry plots from one r-GPA patient. b Percentages of CD45RO-CCR7+ (TNAIVE),
CD45RO+CCR7+ (TCM), CD45RO
+CCR7- (TEM) and CD45RO
-CCR7- (TTD) subpopulations within the CD4
+ T cell population in peripheral blood of HCs
(open circles; n = 42) and r-GPA patients (filled squares; n = 63). c The percentage of CD4+ TEM cell subsets in peripheral blood of HCs (open circles;
n = 42) and r-GPA patients (filled squares; n = 63). Black squares indicate r-GPA patients on treatment (n = 29), grey squares indicate r-GPA patients
off treatment (n = 34). Horizontal lines represent median percentages. *p < 0.05, **p < 0.01, and ***p < 0.001. CCR C-C chemokine receptor, CD cluster
of differentiation, CXCR3 CXC chemokine receptor 3, HC healthy control, r-GPA GPA patient in remission, TEM effector memory T cell
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into patients not receiving immunosuppressive treatment
(off treatment; n = 34), and patients that did receive im-
munosuppressive treatment (on treatment; n = 29) (Fig. 1c).
No significant differences were observed in the frequencies
of TEM1 cells between the untreated and treated r-GPA pa-
tients (median 12.3%, interquartile rang 9.5–17.8% vs 9.0%,
5.6–19.2%). In addition, no significant differences were de-
tected in the frequencies of TEM17 cells between untreated
and treated r-GPA patients (22.3%, 18.0–26.5% vs 26.5%,
17.2–35.4%). Therefore, immunosuppressive treatment at
time of sampling was not responsible for the imbalances
observed between the TEM1 and TEM17 cell subsets.
The influence of S. aureus and CMV infection on the
frequencies of circulating TEM1 and TEM17 cells in GPA
patients
Physiologically, TH17 cells are important in the defense
against bacterial infection (e.g. Staphylococcus aureus
(S. aureus)), by IL-17-mediated activation of neutro-
phils. Interestingly, chronic nasal carriage of S. aureus
has been suggested to drive the TH17 response in
ANCA-associated vasculitis (AAV) [30]. Therefore we
investigated whether chronic nasal carriage of S. aureus
influenced the proportions of TEM1 and TEM17 cells.
No significant differences were found in the proportion
of TEM1 and TEM17 cells between r-GPA patients with
or without S. aureus nasal carriage (Fig. 3a), even after
excluding co-trimoxazole treatment (data not shown).
Besides bacterial infections, latent viral infection can
also influence the T cell compartment in humans. The
expansion in CD4+ TEM cells in GPA patients has been
suggested to be driven by latent cytomegalovirus (CMV)
[15]. Here, we found a slight increase in the percentage
of circulating CD4+TEM cells of CMV-seropositive com-
pared to CMV-seronegative populations. This difference
was statistically significant in r-GPA patients (p = 0.044),
but not in HCs (p = 0.234) (Fig. 3b). In addition, both
CMV-seropositive and CMV-seronegative r-GPA patients
showed significantly increased percentages of CD4+TEM
cells compared to CMV-seropositive HCs.
To investigate the possibility that the shift from TH1
toward TH17 cells in GPA patients was the result of CMV
carriage, we compared the proportions of TEM1 and TEM17
cells between CMV-seropositive and CMV-seronegative
r-GPA patients. As shown in Fig. 3c, CMV-seropositive r-
GPA patients demonstrated significantly higher frequen-
cies of TEM1 cells and significantly lower frequencies of
TEM17 cells compared to CMV-seronegative r-GPA pa-
tients. In contrast, CMV serostatus in HCs did not change
the proportions of TEM1 cells but a small decrease in the
percentage of TEM17 cells in CMV-seropositive HCs
compared to CMV-seronegative HCs was observed.
Furthermore, CMV-specific serum IgG levels in r-GPA
patients showed a positive correlation with the percent-
age of TEM1 cells (Spearman’s rho = 0.408, p < 0.001) and
a negative correlation with the percentage of TEM17 cells
(Spearman’s rho = −0.468, p < 0.0001).
Association of TEM1 and TEM17 frequencies with
laboratory and clinical parameters
We next explored whether disturbed frequencies in
TEM1 and TEM17 cells correlated with various laboratory
Fig. 2 TEM17 cells negatively correlate with TEM1 cells. Correlation between the percentage of TEM17 cells and TEM1 (left), TEM2 (middle) and
TEM17.1 (right) cells within the CD4
+TEM cell population of a r-GPA patients (filled squares; n = 63), black squares patients on treatment (n = 29) and
grey squares patients off treatment (n = 34) and b HC (open circles; n = 42). Correlations were determined by Spearman’s correlation coefficient
(rho) and the level of significance is indicated by the p value. CD cluster of differentiation, HC healthy control, r-GPA GPA patient in remission, TEM
effector memory T cell
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and clinical parameters of r-GPA patients (Table 2).
Serum ANCA titers in GPA patients have often been
related to disease activity and risk of relapse. Therefore,
we investigated the relation between ANCA titer at time
of sampling and the proportions of TEM1 and TEM17
cells in r-GPA patients. No correlation was observed be-
tween ANCA titers and the frequencies of either TEM1
cells or TEM17 cells. In addition, no correlations were
found between frequencies of either TEM1 cells or
TEM17 cells and any other laboratory parameter mea-
sured at the time of inclusion, including creatinine
levels, C-reactive protein (CRP) serum levels, and epi-
dermal growth factor receptor (eGFR).
Interestingly, the accumulating number of organs in-
volved over the total disease course correlated negatively
with the frequency of TEM1 cells (Spearman’s rho = -0.264,
p = 0.037) but correlated positively with TEM17 cells
(Spearman’s rho = 0.390, p = 0.002). In addition, general-
ized r-GPA patients showed lower frequencies of TEM1
cells in comparison to localized r-GPA patients (10.7%,
6.3–16.5% vs 17.9%, 12.6–20.4%, p = 0.016). The
frequencies of TEM17 cells were higher in generalized r-
GPA compared to localized r-GPA patients (24.8%, 19.2–
30.8% vs 19.3%, 15.0–21.4%, p = 0.037). This indicates that
r-GPA patients with more systemic manifestations have
an increased TEM17-mediated immune response, whereas
r-GPA patients with more local manifestations have a
more TEM1-directed immune response. However, disease
duration and total number of relapses did not correlate
with either the frequencies of TEM1 cells or TEM17 cells.
Of note, we observed that r-GPA patients that did en-
counter one or more relapses after diagnosis (1 ≥ relapse
r-GPA, n = 43) had higher frequencies of circulating
TEM17 cells and lower frequencies of circulating TEM1
cells in comparison to r-GPA that experienced no re-
lapse (non-relapse r-GPA, n = 20) since diagnosis
(Fig. 4).
Interaction of CMV serostatus and age on the different T
cell subsets
The results described above regarding the differences be-
tween r-GPA patients and HCs in percentage of CD4+TEM
Fig. 3 TEM1 and TEM17 cell distribution between r-GPA patients with S. aureus nasal carriage and latent CMV infection. a The circulating percentage
of TEM1 and TEM17 cells within the CD4
+TEM cell population in peripheral blood of S. aureus-non-carrying r-GPA patients (open squares; n = 35) and
carrying r-GPA patients (filled squares; n = 27). b The circulating percentage of CD4+TEM cells within the CD4
+ T cell population in peripheral blood,
and c the circulating percentage of TEM1 and TEM17 cells within the CD4
+TEM cell population in peripheral blood of HC CMV-seronegative (open circles;
n = 15), CMV-seropositive (filled circles; n = 21), r-GPA patients CMV-seronegative (open squares; n = 28), and CMV-seropositive (filled squares; n = 33).
Horizontal lines represent median percentages. *p < 0.05, **p < 0.01, and ***p < 0.001. CD cluster of differentiation, CMV cytomegalovirus, HC healthy
control, ns not significant, r-GPA GPA patient in remission, S. aureus, Staphylococcus aureus, TEM effector memory T cell
Table 2 Associations of TEM1 cell and TEM17 cell percentages with clinical parameters
Clinical parameters % TEM1 cells % TEM17 cells
Spearman’s rho p value Spearman’s rho p value
PR3-ANCA titer 0.026 0.839 −0.048 0.707
Creatinine (umol/L) −0.039 0.759 0.164 0.198
CRP (mg/L) 0.047 0.715 0.015 0.909
eGFR (mL/min*1.73 m2) −0.079 0.540 −0.006 0.962
Disease duration (years) −0.023 0.857 0.063 0.626
No. of total relapses −0.148 0.246 0.181 0.155
No. of organs involved −0.264* 0.037 0.390** 0.002
CRP C-reactive protein, eGFR estimated glomerular filtration rate, PR3-ANCA antineutrophil cytoplasmic antibodies targeting proteinase 3, TEM effector memory
T cell
* p < 0.05 and ** p < 0.01
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cells, TEM1 and TEM17 cells may indicate a possible inter-
action between CMV and age, as both factors influence the
T cell memory compartment. To analyze this interaction a
linear regression was performed that included interaction
of CMV and age. This analysis demonstrated that differ-
ences in CD4+TEM cells, TEM1 cells, and TEM17 cells be-
tween r-GPA patients and HCs were not attributed to
CMV serostatus and age (see Additional file 1). Moreover,
differences in TEM1 between relapse r-GPA patients and
non-relapse r-GPA patients were not affected by CMV ser-
ostatus and age. The difference in TEM17 cells between re-
lapse r-GPA patients and non-relapse r-GPA patients was
minimally influenced by CMV serostatus and age as the dif-
ferences for both factors were borderline significant.
Thus, CMV and age did not influence the differences
in expansion of CD4+TEM cells, TEM1 cells, and TEM17
cells, in both r-GPA patients and HCs.
Discussion
In this study, we aimed to determine the distribution of
circulating CD4+ TEM cell subsets based on chemokine re-
ceptor expression in GPA patients. We demonstrated a
significant increase in the proportion of TEM17 cells with
a concomitant decrease in the proportion of TEM1 cells in
peripheral blood of patients with r-GPA. Increased pro-
portions of TEM17 cells were more pronounced in r-GPA
patients with systemic manifestations, whereas r-GPA
patients with local manifestations showed a remarkable
increase in TEM1 cells. Interestingly, CMV seropositivity
appeared to modulate the disturbed balance of TEM1 and
TEM17 cells in r-GPA patients.
The decreased proportions of TEM1 cells in r-GPA
patients compared to HCs reflect an aberrant TEM1
response in patients. It has been demonstrated that GPA
patients with active or localized disease show a polarization
toward a TH1-type response [8, 11, 31]. These studies
showed an abundant TH1 cytokine (IFN-γ) and chemokine
(CCR5) pattern on circulating T cells, as well as in granu-
lomatous lesions compared to patients in remission or with
generalized disease [11, 31]. It has been suggested that the
disturbed TH1 response might play a role in the initiation
of GPA. The disease can progress into a generalized GPA
with a less prominent TH1-type response. The majority of
r-GPA patients included in this study present generalized
disease with a median disease duration of 9.6 years. This
might explain the decreased proportion of circulating TEM1
cells in our r-GPA patients. However, one may also argue
that the relative decrease in circulating TEM1 cells is due to
an increased tissue migration of these cells. In GPA patients
with generalized disease it has been reported that renal le-
sions show polarization toward TH1 type-responses [32].
However, we did not observe an association of TEM1 cells
with renal involvement in r-GPA patients.
Our results regarding the increase in TEM17 response in
GPA patients are in line with previous reports on
increased TH17-associated activity in these patients. It has
been reported that antigen-specific TH17 cells are ex-
panded in GPA patients, irrespective of disease activity
and maintenance therapy [13, 33]. In addition, serum IL-
17A levels are also found to be elevated in active GPA pa-
tients and remained elevated in GPA patients recovering
from active disease [12]. In line with this result, we ob-
served a sustained TEM17 expansion over a period of
6 months in our r-GPA patients. Altogether, the involve-
ment of TH17 cells in the immunopathology in GPA ap-
pears to be well established, although presently it remains
unclear which mechanisms initiate TH17 responses in
GPA. Possible explanations for the expanded TEM17
population might be related to the presence of granu-
lomas, or chronic nasal carriage of S. aureus in GPA.
Granulomas are sophisticated and highly organized
structures that typically consist of a sphere of highly
activated macrophages surround by T lymphocytes.
They provide a specialized niche for macrophage-T cell
Fig. 4 TEM1 and TEM17 cell distribution between relapsing and non-relapsing r-GPA patients. The circulating frequencies of TEM1 and TEM17 cells within
the CD4+TEM cell population in peripheral blood of non-relapsing r-GPA patients (open squares; n = 20) and r-GPA patients that experienced≥ 1 relapse
during their disease course until inclusion in this study (filled squares; n = 43). Horizontal lines represent median percentages. *p < 0.05. CD cluster of
differentiation, r-GPA GPA patient in remission, TEM effector memory T cell
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interaction, contributing to the differentiation and matur-
ation of T cells [34]. The pro-inflammatory cytokine envir-
onment in granuloma may contribute to the aberrant TH1
and TH17 cell distribution found in the circulation. Since,
granulomas are common clinical manifestations in GPA
patients they may provide an ideal environment for
TEM17 cell expansion. Engagement of CD4
+TEM cells with
IL-6/TGFβ-producing macrophages may promote CD4
+TEM cell differentiation into TEM17 cells. In addition,
macrophages also secrete IL-23, which sustains the TH17
population. Indeed, elevated serum levels of TGFβ, IL-6,
and IL-23 have been reported in GPA, and, importantly,
elevated levels of IL-23 correlated with disease severity in
patients with GPA [12].
Chronic carriage of S. aureus constitutes a risk factor
for the development of exacerbations in GPA. We have
previously shown that the frequency of chronic nasal car-
riage of S. aureus is higher in GPA patients compared to
HC [30]. Moreover, it was shown that nasal S. aureus car-
riage is associated with increased risk of relapse [30, 35].
Staphylococcal superantigens act as potent immune stim-
ulators for T cells, resulting in polyclonal T cell prolifera-
tion and pro-inflammatory cytokine production [36]. In
vitro studies demonstrated that stimulating T cells with
staphyloccal exotoxins (alpha-toxin and SEB), strongly
induced IL-17A-secreting T cells [13, 37]. Therefore, the
involvement of TH17 cells in GPA may possibly be driven
by chronic nasal carriage of S. aureus. However, we did
not observe increased frequencies of TEM17 cells in GPA
patients carrying S. aureus. This observation is in line with
earlier studies in GPA patients in which no correlation
between the presence of staphylococcal superantigens and
the expansion of T cell subsets in peripheral blood was
found [27].
Remarkably, we observed that the proportion of
TEM17 cells in r-GPA patients was highly associated with
CMV serostatus with frequencies of TEM17 cells being
decreased in CMV-seropositive r-GPA patients as com-
pared to seronegative r-GPA patients. These observa-
tions indicate that latent infection with human CMV
modulates the distribution of TEM cell subsets, although
the underlying mechanisms are unclear. For instance,
CMV seropositivity is strongly associated with the pres-
ence of memory T cells. It has been demonstrated that
only CMV-seropositive individuals possess significant
numbers of CD4+CD28- T cells and many of these T cells
respond to CMV [38]. In fact, the expansion of CD4
+CD28- T cells in GPA is suggested to be driven by
CMV infections, and is associated with increased risk of
infection and mortality [15]. However, the precise role of
CMV infection in TH1 and TH17 responses is poorly
understood. Previous studies indicate that T cells ex-
pressing CXCR3 (TH1 type) arise during primary CMV
infection and are maintained during latency [39]. In line
with this study, we observed increased proportions of
TEM1 cells in the circulation of CMV-seropositive r-GPA
patients. The skewing toward a TEM1 response in CMV-
seropositive r-GPA patients could also explain the de-
crease in the proportion of TEM17 cells since these two
TEM cells subsets inversely correlate with each other.
Importantly, the difference in TEM1 cells between r-GPA
patients and HCs was not influenced by CMV and age.
Additionally, CMV serostatus did not influence the
proportions of TEM1 cells in HCs whereas in r-GPA
patients CMV serostatus had a major impact on both
the proportions of TEM1, and TEM17 cells.
TH17 cells may also induce autoimmune responses.
Very recently, it was shown that the frequency of TH17
cells (CCR6+) in rheumatoid arthritis (RA) patients is as-
sociated with anti-citrullinated protein antibodies (ACPA)
status [28]. In particular, CCR6+ TH cell proportions were
higher in ACPA-positive RA patients in comparison to
ACPA-negative RA patients, and inversely correlated with
disease duration in ACPA-negative patients. If this were
the case in GPA patients, one may argue that the increase
in TEM17 cells might be associated with ANCA status and
could be a tool to discriminate ANCA-positive patients
from those that are ANCA-negative. In contrast to the
data in RA patients, we did not observe any association
regarding ANCA status with the frequency of TEM17 cells
in r-GPA patients. This is possibly due to the fact that
ANCA titers in GPA patients fluctuate during the disease
course, whereas ACPA-positive RA patients consistently
remain ACPA-positive over time. On the other hand, we
found that TEM17 cells in GPA patients showed a positive
association with organ involvement, whereas TEM1 cells
were negatively associated with organ involvement. This
suggests a more severe disease course in individuals with
a high frequency of TEM17 cells. Furthermore, we
observed that persistent TEM17 expansion is associated
with a higher tendency to relapse.
The current study was designed as a cross-sectional
study using peripheral blood of quiescent GPA patients
and HCs. The main limitations are the lack of absolute
lymphocyte counts and study samples from GPA pa-
tients with active disease. Therefore, the current data
only provides observational information of proportions
of circulating CD4+ TEM cell subsets in r-GPA patients.
Further studies are warranted to assess blood samples
from patients during active disease and to study the
distribution of infiltrated TEM cell subsets in nasal and
renal biopsies to elucidate distinct migratory capacities
of TEM1 and TEM17 cells and to confirm their role in
inflamed target tissues in GPA. Since TEM cells also
appear in the urine during active renal GPA disease,
analysis of urine samples might aid in demonstrating
which distinct TEM subsets are possibly involved in
renal injury.
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Conclusions
This study describes the distribution of circulating CD4+
TEM cell subsets identified based on chemokine receptor
expression in r-GPA patients without any in vitro ma-
nipulation. It demonstrates an aberrant balance between
TEM1 and TEM17 cells in r-GPA patients, which is
shown to be associated with severity of the disease in
terms of organ involvement, and tendency to relapse.
Interestingly, the imbalance between TEM1 and TEM17
cells is modulated in CMV-seropositive r-GPA patients.
Accordingly, future T cell phenotype studies should
take into account chronic viral infections (i.e. CMV)
for CD4+TEM subset characterization.
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